Receive our newsletter – data, insights and analysis delivered to you
July 22, 2009

GSK and Enigma to Develop Rapid Flu Test

GlaxoSmithKline (GSK) and Enigma Diagnostics Limited have announced an agreement to develop and supply the first point-of-care diagnostic test to identify specific influenza virus strains. GSK and Enigma will develop the test with the Enigma ML mini laboratory using the real-time polymera

By cms admin

GlaxoSmithKline (GSK) and Enigma Diagnostics Limited have announced an agreement to develop and supply the first point-of-care diagnostic test to identify specific influenza virus strains.

GSK and Enigma will develop the test with the Enigma ML mini laboratory using the real-time polymerase chain reaction (PCR) technology platform, which is capable of delivering fully automated results from swab samples in less than 60 minutes with the same accuracy standards as reference laboratories.

The system will speed up treatment for patients, who often have to wait several days before the results of government laboratory tests are available.

A trial of the ML system across Europe will commence in Q4 2009. Launch of Enigma ML is anticipated in early 2011, subject to successful clinical trials and regulatory approval.

GSK European Pharmaceuticals business president Eddie Gray said that the technology is promising and has the potential to ensure that patients are diagnosed accurately and rapidly and that they receive the most appropriate treatment in a timely manner.

“This could also play a key part in enabling governments to support critical workers to fulfil their roles during a pandemic as well as facilitate sensitive influenza surveillance – key to the identification of novel strains and optimal utilisation of antiviral medication,” Gray said.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

As part of the agreement, GSK will make a small equity investment in Enigma. The deal also includes an upfront payment, research and development funding and profit sharing on sales. Further payments will be subject to development progress and agreed milestones.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU